Oncology Institute (DFPH) EBITDA (2020 - 2026)

Oncology Institute (DFPH) has reported EBITDA for 7 consecutive years, with -$5.6 million the latest figure, recorded in Q1 2026.

• EBITDA for Q1 2026 came in at -$5.6 million, up 36.94% year-over-year; the trailing twelve-month figure through Mar 2026 was -$28.8 million (up 40.64% YoY), and the FY2025 annual result was -$32.1 million, up 43.58% from the prior year.
• EBITDA was -$5.6 million for Q1 2026 at Oncology Institute, up from -$6.0 million in the prior quarter.
• Over five years, EBITDA peaked at -$5.6 million in Q1 2026 and troughed at -$32.3 million in Q1 2023.
• Average EBITDA over 5 years is -$14.7 million, with a median of -$14.3 million recorded in 2023.
• Year-over-year, EBITDA plunged 1802.97% in 2022 and surged 48.43% in 2025.
• Over 5 years, EBITDA stood at -$24.6 million in 2022, then soared by 41.18% to -$14.5 million in 2023, then grew by 24.06% to -$11.0 million in 2024, then soared by 45.51% to -$6.0 million in 2025, then grew by 6.34% to -$5.6 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$5.6 million in Q1 2026, -$6.0 million in Q4 2025, and -$7.0 million in Q3 2025.